快速起效抗抑郁药在双相抑郁中作用的当前证据:视角与行动计划
本文综述了快速起效抗抑郁药(RAADs)在双相抑郁中的研究现状,涵盖已发表研究及ClinicalTrials.gov注册的II、III、IV期试验。涉及NMDA拮抗剂与间接AMPA激动剂、GABAA激活剂或正性变构调节剂、致幻剂、毒蕈碱受体拮抗剂及κ阿片受体拮抗剂等类别。除(艾)氯胺酮在双相抑郁中的疗效与安全性已确立外,该领域研究仍较少,亟需良好对照的临床研究。
要点
- (艾)氯胺酮在双相抑郁中的疗效与安全性已确立,但其他RAADs研究 scarce。
- 多种RAADs类别正在或曾被研究作为双相抑郁的可能治疗。
- 亟需良好对照的临床研究以扩大治疗选择并改善结局。
核心结论
- 除(艾)氯胺酮在双相抑郁中的疗效与安全性已确立外,针对双相抑郁的治疗研究投入很少。
- 近期对RAADs的研究显示双相抑郁药物治疗中新作用机制领域正在增长。
- 亟需关于RAADs在双相抑郁中的良好对照临床研究,以扩大治疗选择并改善全球数百万患者的结局。
研究设计与样本
- 本综述概述了RAADs在双相障碍背景下的当前进展,回顾了已发表研究以及基于ClinicalTrials.gov的双相抑郁II、III、IV期研究。
主要发现
- 以下RAAD物质类别已被或目前正在被研究作为双相抑郁的可能治疗:NMDA拮抗剂与间接AMPA激动剂(氯胺酮、艾氯胺酮、利鲁唑、非尔氨酯)、GABAA激活剂或正性变构调节剂(zuranolone、孕烯醇酮、PEA)、致幻剂(赛洛西宾、5-MeO-DMT)、毒蕈碱受体拮抗剂(东莨菪碱)及κ阿片受体拮抗剂(navacaprant)。
- 除(艾)氯胺酮在双相抑郁中的疗效与安全性已确立外,针对双相抑郁的治疗研究投入很少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 除(艾)氯胺酮在双相抑郁中的疗效与安全性已确立外,针对双相抑郁的治疗研究投入很少。
- 亟需关于RAADs在双相抑郁中的良好对照临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression due to the reduced risk of mania induction, research on RAADs, such as (es)ketamine, remains scarce despite their demonstrated safety and effectiveness. In this review, we give an overview of current developments in RAADs in the context of bipolar disorder. Both published studies as well as phase II, III, and IV studies on bipolar depression (based on ClinicalTrials.gov) are reviewed in this work. The following RAAD substance classes have been or are currently being investigated as possible treatments for bipolar depression: NMDA antagonists and indirect AMPA agonists (ketamine, esketamine, riluzole, felbamate), GABAA (gamma-aminobutyric acid A) activators or positive allosteric modulators (zuranolone, pregnenolone, PEA), psychedelics (psilocybin, 5-MeO-DMT), muscarine receptor antagonists (scopolamine), and kappa opioid receptor antagonists (navacaprant). Other than the well-established efficacy and safety of (es)ketamine in treating bipolar depression, there has been little research effort in the treatment of bipolar depression. Recent research into RAADs demonstrates the growing field of novel mechanisms of action in the pharmacological treatment of bipolar depression. However, there is an urgent need for well-controlled clinical studies on RAADs in bipolar depression to expand treatment options and improve outcomes for millions of affected individuals worldwide.
引用
- Repple J, Bayas M, Möser C, et al. Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action. Biol Psychiatry. 2025. PMID: 40064389. doi:10.1016/j.biopsych.2025.02.903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。